Image for Epigenetics for drug discovery

Epigenetics for drug discovery - No. 48

Baylin, Stephen(Contributions by)Butler, Paul(Contributions by)Chung, Chun-Wa(Contributions by)Heightman, Tom(Contributions by)Ma, Haiching(Contributions by)Murrell, Adele(Contributions by)Nightingale, Karl(Contributions by)Trojer, Patrick(Contributions by)Turner, Brian(Contributions by)Verhelle, Dominique(Contributions by)Vitt, Daniel(Contributions by)Zhang, Hui(Contributions by)Carey, Nessa(Edited by)Fox, David(Series edited by)
Part of the RSC Drug Discovery series
See all formats and editions

Epigenetics is one of the fastest moving fields in drug discovery, with almost every large pharmaceutical company and a substantial number of biotechnology companies targeting epigenetic processes to treat diseases ranging from cancer to Huntington's disease and from inflammation to sickle cell anaemia.

The book introduces epigenetics and explains the importance at both a phenomenological and molecular level, reviews the breakthroughs in the field, and highlights the ongoing challenges in creating safe and effective epigenetic drugs.

Read More
Special order line: only available to educational & business accounts. Sign In
£179.00
Product Details
Royal Society of Chemistry
1782628487 / 9781782628484
eBook (Adobe Pdf)
572.865
20/11/2015
England
English
316 pages
Copy: 20%; print: 20%